Maxalt (Rizatriptan Benzoate)

Rizatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that generates migraine.

The dose of Maxalt is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of rizatriptan in pregnancy and lactation has not been established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Maxalt.

To order Maxalt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxalt belongs to the Triptan class, which is generally more effective for moderate to severe migraine attacks than non‑specific analgesics such as NSAIDs. Compared with other triptans, rizatriptan has a rapid onset of action, but individual response can vary, so clinicians choose based on efficacy, tolerability and patient history.

Store Maxalt tablets at ambient temperature, below 25 °C, in a dry place. Keep the tablets in the original blister pack to protect them from moisture and light. Do not store in the bathroom or near heat sources.

Maxalt is taken orally with a glass of water. The tablet should be swallowed whole and can be taken with or without food. Patients should follow the timing recommended by their prescriber, typically at the onset of migraine symptoms.

Serious risks include coronary vasospasm, which can cause chest pain, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience severe chest discomfort, rapid heart rate, high fever, agitation, or muscle rigidity.

Maxalt should not be used by individuals with uncontrolled cardiovascular disease, a history of myocardial infarction, severe hepatic impairment, or those taking other triptans, ergot derivatives, or monoamine oxidase inhibitors. It is also contraindicated in patients with known hypersensitivity to rizatriptan.